Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer [Urologic Oncology]

Conclusion
In chemotherapy-naïve men with mCRPC, tasquinimod significantly improved rPFS compared with placebo. However, no OS benefit was observed.

Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Authors: Sternberg, Armstrong, Pili, Ng, Huddart, Agarwal, Khvorostenko, Lyulko, Brize, Vogelzang, Delva, Harza, Thanos, James, Werbrouck, Bogemann, Hutson, Milecki, Chowdhury, Gallardo, Schwartsmann, Pouget, Baton, Nederman, Tuvesson, Carducci Tags: Systemic Therapy Urologic Oncology Source Type: research